Marshall Wace, LLP Intra Cellular Therapies, Inc. Transaction History
Marshall Wace, LLP
- $78.4 Billion
- Q4 2024
A detailed history of Marshall Wace, LLP transactions in Intra Cellular Therapies, Inc. stock. As of the latest transaction made, Marshall Wace, LLP holds 1,079,757 shares of ITCI stock, worth $138 Million. This represents 0.11% of its overall portfolio holdings.
Number of Shares
1,079,757
Previous 1,160,973
7.0%
Holding current value
$138 Million
Previous $84.9 Million
6.23%
% of portfolio
0.11%
Previous 0.11%
Shares
16 transactions
Others Institutions Holding ITCI
# of Institutions
418Shares Held
88.6MCall Options Held
284KPut Options Held
105K-
Vanguard Group Inc Valley Forge, PA9.72MShares$1.25 Billion0.01% of portfolio
-
Black Rock Inc. New York, NY6.32MShares$810 Million0.01% of portfolio
-
Jpmorgan Chase & CO New York, NY5.13MShares$657 Million0.03% of portfolio
-
Wasatch Advisors Inc Salt Lake City, UT3.25MShares$416 Million1.36% of portfolio
-
Norges Bank Oslo, Q83.21MShares$412 Million0.04% of portfolio
About Intra-Cellular Therapies, Inc.
- Ticker ITCI
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 94,401,696
- Market Cap $12.1B
- Description
- Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in dev...